Update on adjuvant therapy in completely resected NSCLC patients

Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer

(2021) Fangqiu Fu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial

(2021) Leonetti Alessandro et al.   Clinical Lung Cancer

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures

(2021) Tao Shi et al.   Frontiers in Oncology

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

(2021) Justin M. Burgener et al.   CLINICAL CANCER RESEARCH

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

(2021) Heather A. Wakelee et al.   JOURNAL OF CLINICAL ONCOLOGY

The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study

(2021) Tomo Sato et al.   LUNG CANCER

Neoantigen load as a prognostic and predictive marker for stage II / III non‐small cell lung cancer in Chinese patients

(2021) Lei Gong et al.   Thoracic Cancer

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

(2021) Zhouguang Hui et al.   JAMA Oncology

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

(2021) Abdul Rahman Jazieh et al.   Journal of Thoracic Oncology

Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung

(2020) Yuko Tashima et al.   Scientific Reports

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

(2020) Yu-Tao Liu et al.   Cancer Management and Research

LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

(2020) C. Le Pechoux et al.   ANNALS OF ONCOLOGY

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

(2020) Muyun Peng et al.   Frontiers in Oncology

Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non–small-cell Lung Cancer

(2019) Masaki Nakamura et al.   Clinical Lung Cancer

Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging

(2019) Johannes R. Kratz et al.   Journal of Thoracic Oncology

Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer

(2019) Shinya Katsumata et al.   Journal of Thoracic Oncology

Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung

(2019) Thomas Muley et al.   LUNG CANCER

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer

(2019) Georgios Tsakonas et al.   LUNG CANCER

Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non–Small-Cell Lung Cancer

(2018) Samual Francis et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma

(2018) Sun Hye Shin et al.   Journal of Thoracic Disease

Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non–small cell lung cancer

(2018) Juliana Machado-Rugolo et al.   HUMAN PATHOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

(2018) Dongsheng Yue et al.   Lancet Respiratory Medicine

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer

(2018) Yang Xie et al.   CLINICAL CANCER RESEARCH

The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA non-small cell lung cancer

(2018) Chongze Yuan et al.   JOURNAL OF SURGICAL ONCOLOGY

Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer

(2018) Jyothi Thyagabhavan Mony et al.   Frontiers in Immunology

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

(2016) Peter Goldstraw et al.   Journal of Thoracic Oncology

Factors predicting organ-specific distant metastasis in patients with completely resected lung adenocarcinoma

(2016) Jung-Jyh Hung et al.   Oncotarget

Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery

(2015) Jacquelyn G. Hancock et al.   ANNALS OF THORACIC SURGERY

Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer

(2013) Liang Zhang et al.   Thoracic Cancer

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

(2012) Johannes R Kratz et al.   LANCET

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

(2010) Noriyasu Usami et al.   International Journal of Clinical Oncology

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

(2009) Rodrigo Arriagada et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY